Cover Image
市場調查報告書

前列腺癌治療藥的價格·給付·使用趨勢

Prostate Cancer Pricing, Reimbursement, and Access

出版商 Datamonitor Healthcare 商品編碼 365152
出版日期 內容資訊 英文 161 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
前列腺癌治療藥的價格·給付·使用趨勢 Prostate Cancer Pricing, Reimbursement, and Access
出版日期: 2016年07月05日 內容資訊: 英文 161 Pages
簡介

本報告調查美國·日本·歐盟5國 (法國·德國·義大利·西班牙·英國) 前列腺癌治療藥的價格·給付·使用趨勢,提供您主要國家已上市的主要產品,開發後期階段的開發平台,全球保險者及KOL (關鍵意見領袖) 的見解,並彙整各國藥價決策·給付·利用相關趨勢。

摘要整理

市場背景

  • 市場已上市前列腺癌治療藥:美國·日本·EU主要5個國家
  • 後期開發階段的開發平台前列腺癌治療藥
  • 參考文獻

全球保險者·KOL (關鍵意見領袖)的考察

  • 考察·策略性建議
  • 保險業者的典型和使用趨勢
  • 非轉移性閹割抗性前列腺癌
  • 轉移性荷爾蒙無效前列腺癌
  • 由於在整體資源使用上展現出初期或是聯合治療的影響,而讓保險業者氣勢漸增
  • 特別在Xofigo上,患者報告結果越發重要
  • 類似的新抗雄激素與其他有所不同
  • 供應商比起順次性使用治療藥更在意並用藥可否提供長期治療成果
  • 總括付款制度的到來,促進最佳治療途徑方面資料的需求
  • 新免疫療法·疫苗是受歡迎的替代藥,但面臨與前列腺癌治療用疫苗「Provenge (Provenge)」同樣的課題
  • 參考文獻

美國的價格趨勢

  • 美國的價格趨勢:成本控制的方向性
  • 參考文獻

美國的保險者及KOL的考察

  • 考察·策略性建議
  • 參考文獻、其他

美國的報銷問題

  • 考察·策略性建議
  • NCCN指南反映FDA標籤
  • 參考文獻、其他

日本

  • 對補充利益或創新的補貼價格
  • 已上市前列腺癌治療藥的價格
  • 參考文獻

EU主要5個國家市場上價格

EU主要5個國家的保險者及KOL分析

  • 考察·策略性建議
  • 主要趨勢
  • 參考文獻

法國

德國

義大利

西班牙

英國

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0162106

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response measures and unattractive dosing.

This report addresses the following questions:

  • How do access restrictions for prostate cancer drugs differ across markets and why?
  • Which clinical trial comparators and outcomes are necessary for approval and uptake in each market?
  • What impact, if any, will value assessment tools have on US reimbursement patterns?
  • When and where are risk-sharing agreements useful in gaining market access?
  • What are US and EU payers' and physicians' opinions on drugs targeting non-metastatic CRPC or metastatic HSPC?
  • Which vaccines have a chance for uptake and reimbursement in US and EU markets?
  • What does the future hold for radiotherapy Xofigo?

TABLE OF CONTENTS

EXECUTIVE SUMMARY

MARKET CONTEXT

  • 1. Marketed prostate cancer products in the US, Japan, and five major EU markets
  • 2. Pipeline prostate cancer treatments in late-stage development
  • 3. Bibliography.

GLOBAL PAYER AND KEY OPINION LEADER INSIGHTS

  • 4. Insights and strategic recommendations
  • 5. Payer archetypes and trends in access
  • 5. Non-metastatic castration-resistant prostate cancer
  • 6. Metastatic hormone-sensitive prostate cancer
  • 7. Evidence for the impact of earlier or combination treatment on overall resource use could gain traction with payers
  • 8. Patient-reported outcomes will become increasingly important, particularly for Xofigo
  • 9. Similar novel antiandrogens look to differentiate themselves from one another
  • 10. Providers grapple with whether or not combinations provide better long-term outcomes than sequential use of the drugs
  • 11. Advent of bundled payments will drive the need for data on optimal care pathways
  • 12. Novel immunotherapies and vaccines are welcomed alternatives, but will face similar challenges to Provenge
  • 13. Bibliography

US PRICING

  • 14. Pricing trends in the US look toward greater cost control
  • 15. Bibliography

US PAYER AND KEY OPINION LEADER INSIGHTS

  • 16. Insights and strategic recommendations
  • 17. Insurers commonly reimburse NCCN-backed indications; obtaining a category 1 recommendation will become increasingly important
  • 18. If efficacy and safety data are not differentiated from other drugs, twice-daily dosing may hinder BAY-1841788's potential
  • 19. Jevtana will be restricted to use after docetaxel, unless a substantial benefit is shown in
  • FIRSTANA TRIAL
  • 20. Prescribing patterns differ between medical oncologists and urologists; payers consider management of CRPC by oncologists as ideal
  • 21. Cancer Drug Coverage Parity Act of 2015 could close gap in out-of-pocket costs between oral and inpatient drugs
  • 22. New drugs mean new opportunities for contracting
  • 23. Bibliography

US REIMBURSEMENT

  • 24. Insights and strategic recommendations
  • 25. NCCN guidelines reflect FDA labels
  • 26. NCCN Evidence Blocks
  • 27. Drug value frameworks will guide the formation of clinical pathways and reimbursement
  • criteria in the future
  • 28. Payers have limited utilization management options despite rising costs, but oncology pathways are making inroads
  • 29. Branded prostate cancer therapies are generally found on top tiers as specialty drugs
  • 30. Prior authorization and step therapy criteria from numerous payers restrict the use of Xtandi
  • 31. Bibliography

JAPAN

  • 32. Price premiums are awarded for added benefit or innovation
  • 33. Pricing of launched prostate cancer treatments
  • 34. Bibliography

PRICING IN THE FIVE MAJOR EU MARKETS FIVE MAJOR EU MARKETS PAYER AND KEY OPINION LEADER INSIGHTS

  • 35. Insights and strategic recommendations
  • 36. ESMO drug ratings praise Xofigo, but are uncertain about Xtandi's and Zytiga's role before Docetaxel
  • 37. Jevtana restricted in many European countries due to poor benefit-to-risk ratio
  • 38. Xofigo is restricted to use after docetaxel therapy in most European countries
  • 39. Real-world data are a priority for assessment bodies
  • 40. Bibliography

FRANCE

  • 41. Insights and strategic recommendations
  • 42. ASMR rating has an impact on pricing
  • 43. The majority of new market entrants will be compared to Zytiga
  • 44. While price is a concern, effective and tolerable vaccines will be a welcomed alternative
  • 45. Bibliography

GERMANY

  • 46. Insights and strategic recommendations
  • 47. Positive assessment from the G-BA will impact price negotiations
  • 48. Cell therapies will find entry into the German market at the hospital level through supplemental funding mechanisms
  • 49. Bibliography

ITALY

  • 51. Insights and strategic recommendations
  • 52. All established prostate cancer treatments are reimbursed by AIFA
  • 53. Regional health authorities perform thorough health technology assessments on new drugs
  • 54. Oral drugs subject to monitoring
  • 55. Bibliography

SPAIN

  • 56. Insights and strategic recommendations
  • 57. National reimbursement decisions are not a major access barrier in Spain
  • 58. Regional restrictions tend to align with adverse event profiles and clinical trial exclusion
  • Criteria
  • 59. Spanish Oncology Genitourinary Group recommendations
  • 60. Bibliography

UK

  • 61. Insights and strategic recommendations
  • 62. NICE and SMC assessments drive reimbursement decisions
  • 63. Cancer Drugs Fund
  • 64. Bibliography

APPENDIX

  • 65. Primary research
  • 66. Price assumptions
  • 67. Bibliography
Back to Top